{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:02Z","timestamp":1791327422288,"version":"4.3.1"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Primary and secondary antibody deficiencies (PAD and SAD) are amongst the most prevalent immunodeficiency syndromes, often necessitating long-term immune globulin replacement therapy (IRT). Both intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) have demonstrated efficacy in antibody deficiency. Comparative analyses of these two routes of administration are limited to nurse-administered IVIG and home therapy with self-administered SCIG. A third programmatic approach, SCIG administered by nurses in hospital-based outpatient infusion clinics, combines certain advantages of IVIG and home SCIG such as the provision of nursing support and the reduced risk of systemic reactions associated with the subcutaneous route. This cross-sectional study aimed to compare the viability and resource utilization of nurse-administered SCIG with IVIG in patients with antibody deficiency. We hypothesized that nurse-administered SCIG would require a similar amount of infusion clinic time per month as IVIG, despite more frequent dosing, due to shorter individual appointments, while maintaining high patient satisfaction. Information on infusion duration, time in the infusion chair, direct nursing time, and treatment satisfaction using the Life Quality Index was collected. Time measures for each patient were expressed as minutes\/4 weeks to account for the more frequent dosing of nurse-administered SCIG compared to IVIG. We determined that the total time, infusion time, and nursing time needed to provide nurse-administered SCIG was comparable to IVIG. The more frequent dosing of SCIG was offset by the shorter times required per infusion. Patients reported favorable treatment satisfaction with both nurse-administered SCIG and IVIG. We conclude that nurse-administered SCIG may be a useful treatment modality for well-selected individuals.<\/jats:p>","DOI":"10.1371\/journal.pone.0316797","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T18:50:02Z","timestamp":1736794202000},"page":"e0316797","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Feasibility and resource utilization of nurse-administered subcutaneous immunoglobulin therapy in antibody deficiency: A cross-sectional study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5874-2444","authenticated-orcid":true,"given":"Darshee","family":"Ghia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4290-5764","authenticated-orcid":true,"given":"Pranavi","family":"Thota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heli","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranvir","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Moolji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7612-6529","authenticated-orcid":true,"given":"Adil","family":"Adatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"7","key":"pone.0316797.ref001","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1007\/s10875-022-01352-z","article-title":"The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity","volume":"42","author":"A Bousfiha","year":"2022","journal-title":"Journal of Clinical Immunology"},{"issue":"5","key":"pone.0316797.ref002","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"FA Bonilla","year":"2015","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"pone.0316797.ref003","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"IM Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"pone.0316797.ref004","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1016\/j.jaip.2021.09.031","article-title":"Antibody Deficiency, Chronic Lung Disease, and Comorbid Conditions: A Case-Based Approach","volume":"9","author":"AA Petrov","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"pone.0316797.ref005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","volume":"188","author":"S Jolles","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"pone.0316797.ref006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.iac.2018.08.001","article-title":"Personalized Therapy: Immunoglobulin Replacement for Antibody Deficiency","volume":"39","author":"RL Wasserman","year":"2019","journal-title":"Immunology and Allergy Clinics of North America"},{"issue":"7","key":"pone.0316797.ref007","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1007\/s10875-023-01546-z","article-title":"Late-Onset Lymphopenia and ITP in a Patient with Hyper IgM Syndrome Due to a Homozygous Variant in AICDA","volume":"43","author":"A Adatia","year":"2023","journal-title":"Journal of Clinical Immunology"},{"issue":"7","key":"pone.0316797.ref008","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"ES Resnick","year":"2012","journal-title":"Blood"},{"key":"pone.0316797.ref009","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management","volume":"10","author":"SY Patel","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"pone.0316797.ref010","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10875-012-9740-x","article-title":"Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again","volume":"32","author":"RL Wasserman","year":"2012","journal-title":"Journal of Clinical Immunology"},{"issue":"5","key":"pone.0316797.ref011","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3810\/pgm.2011.09.2474","article-title":"Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases","volume":"123","author":"MR Stein","year":"2011","journal-title":"Postgrad Med"},{"issue":"6","key":"pone.0316797.ref012","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis","volume":"32","author":"H Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"issue":"2","key":"pone.0316797.ref013","first-page":"96","article-title":"Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia","volume":"18","author":"TM Windegger","year":"2020","journal-title":"Blood Transfus"},{"issue":"3","key":"pone.0316797.ref014","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/ped.14119","article-title":"The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents\u2019 \/ caregivers\u2019 satisfaction","volume":"62","author":"J Lechanska-Helman","year":"2020","journal-title":"Pediatr Int"},{"issue":"3","key":"pone.0316797.ref015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/vox.12760","article-title":"Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency","volume":"114","author":"TM Windegger","year":"2019","journal-title":"Vox Sang"},{"issue":"2","key":"pone.0316797.ref016","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.anai.2017.11.002","article-title":"Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis","volume":"120","author":"LW Fu","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"pone.0316797.ref017","first-page":"18","article-title":"Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study","author":"B Ritchie","year":"2022","journal-title":"Allergy, Asthma & Clinical Immunology"},{"issue":"7","key":"pone.0316797.ref018","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s11136-005-1746-x","article-title":"Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy","volume":"14","author":"U Nicolay","year":"2005","journal-title":"Qual Life Res"},{"key":"pone.0316797.ref019","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-023-01546-z","article-title":"Late-Onset Lymphopenia and ITP in a Patient with Hyper IgM Syndrome Due to a Homozygous Variant in AICDA","author":"A Adatia","year":"2023","journal-title":"J Clin Immunol"},{"key":"pone.0316797.ref020","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T \u2010 and a side order of IgG, to go? \u2010 Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"JA Hill","year":"2019","journal-title":"Blood Rev"},{"key":"pone.0316797.ref021","article-title":"IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies","author":"G Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"pone.0316797.ref022","article-title":"ALPI-studien Att Leva med Prim\u00e4r Immunbrist Vuxenrapport. Rapport 1 [The SwePID study; to live with a primary immunodeficiency","author":"HS Gardulf A","year":"2007","journal-title":"Report regarding adults"},{"issue":"2","key":"pone.0316797.ref023","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"S Jolles","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"pone.0316797.ref024","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13223-022-00735-6","article-title":"Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study","volume":"18","author":"B Ritchie","year":"2022","journal-title":"Allergy, Asthma, and Clinical Immunology: Official Journal of the Canadian Society of Allergy and Clinical Immunology"},{"issue":"12","key":"pone.0316797.ref025","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/imt-2017-0092","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases","volume":"9","author":"RL Wasserman","year":"2017","journal-title":"Immunotherapy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T18:50:10Z","timestamp":1736794210000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316797"}},"subtitle":[],"editor":[{"given":"Mehmet","family":"Baysal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0316797","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]}}}